KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $196.5 million.

  • BeOne Medicines' Cost of Revenue rose 1528.08% to $196.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.7 million, marking a year-over-year increase of 2731.32%. This contributed to the annual value of $594.1 million for FY2024, which is 5637.21% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Cost of Revenue is $196.5 million, which was up 1528.08% from $164.6 million recorded in Q2 2025.
  • BeOne Medicines' Cost of Revenue's 5-year high stood at $196.5 million during Q3 2025, with a 5-year trough of $32.7 million in Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $96.0 million (2023), whereas its average is $102.7 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 15346.33% in 2021, then surged by 1528.08% in 2025.
  • BeOne Medicines' Cost of Revenue (Quarter) stood at $48.5 million in 2021, then soared by 51.45% to $73.5 million in 2022, then skyrocketed by 43.95% to $105.8 million in 2023, then soared by 51.71% to $160.6 million in 2024, then increased by 22.39% to $196.5 million in 2025.
  • Its last three reported values are $196.5 million in Q3 2025, $164.6 million for Q2 2025, and $165.0 million during Q1 2025.